Vaccine

Abstract

The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular breast cancer, ovarian cancer and colorectal cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.

1 .- 22 . (canceled) 
     
     
         23 . A pharmaceutical composition, comprising: (i) a peptide having an amino acid sequence comprising that of any of SEQ ID NOs: 332-346; and (ii) a pharmaceutically acceptable adjuvant. 
     
     
         24 . A pharmaceutical composition, comprising: (i) at least a first peptide and a second peptide, each peptide having a different amino acid sequence comprising that of any of SEQ ID NOs: 302-331; and (ii) a pharmaceutically acceptable adjuvant. 
     
     
         25 . The pharmaceutical composition of  claim 24 , further comprising at least one additional peptide, wherein the at least one additional peptide has an amino acid sequence that is: (i) a different sequence from the first and the second peptides of  claim 24 ; and (ii) comprises that of any of SEQ ID NOs: 272-301. 
     
     
         26 . The pharmaceutical composition of  claim 23 , further comprising at least one additional peptide comprising a fragment of an antigen selected from OY-TES-1, PIWIL-2, PIWIL-3, PIWIL-4, BORIS, AKAP4, WT1, HIWI, EpCam, SP17, SPAG9, PRAME, and SURVIVIN. 
     
     
         27 . The pharmaceutical composition of  claim 23 , wherein the peptide is encoded by a nucleic acid molecule. 
     
     
         28 . The pharmaceutical composition of  claim 27 , wherein the nucleic acid molecule is selected from DNA and RNA. 
     
     
         29 . The pharmaceutical composition of  claim 27 , wherein the nucleic acid molecule is RNA. 
     
     
         30 . The pharmaceutical composition of  claim 29 , wherein the RNA: (i) is selected from non-replicating mRNA or virally-derived, self-amplifying RNA; and/or (ii) comprises a non-naturally occurring nucleotide or a modified nucleoside. 
     
     
         31 . A method of treating ovarian cancer, comprising administering the pharmaceutical composition of  claim 23  to an individual in need thereof. 
     
     
         32 . A pharmaceutical composition, comprising: (i) at least a first peptide and a second peptide, each peptide having a different amino acid sequence comprising that of any of SEQ ID NOs: 41-60, 64, or 195-233; and (ii) a pharmaceutically acceptable adjuvant. 
     
     
         33 . The pharmaceutical composition of  claim 32 , wherein the combination of the first peptide and the second peptide has an amino acid sequence comprising that of any of SEQ ID NOs: 81-111 or 435-449. 
     
     
         34 . The pharmaceutical composition of  claim 33 , further comprising at least one additional peptide, wherein the at least one additional peptide has an amino acid sequence that is: (i) a different sequence from the first and the second peptides of  claim 33 ; and (ii) comprises that of any of SEQ ID NOs: 1-20, or 175-194. 
     
     
         35 . The pharmaceutical composition of  claim 32 , further comprising at least one additional peptide comprising a fragment of an antigen selected from TSGA10, PIWIL-2, AKAP4, PLU-1, RHOXF-2, SPAG9, EpCam, HIWI, ODF-4, NY-SAR-35, RHOXF-2, PRAIVIE, MAGE-A9, MAGE-A11, SP17, BORIS, Survivin, HOM-TES-95, NY-BR-1, and NY-ESO-1. 
     
     
         36 . The pharmaceutical composition of  claim 32 , further comprising at least one additional peptide comprising a fragment of an antigen selected from AKAP4, BORIS, SPAG9, NY-SAR-35, PRAME, SURVIVIN, MAGE-A9, MAGE-A11, NY-BR-1, and HomTes85. 
     
     
         37 . The pharmaceutical composition of  claim 32 , wherein the peptide is encoded by a nucleic acid molecule. 
     
     
         38 . The pharmaceutical composition of  claim 37 , wherein the nucleic acid molecule is selected from DNA and RNA. 
     
     
         39 . The pharmaceutical composition of  claim 37 , wherein the nucleic acid molecule is RNA. 
     
     
         40 . The pharmaceutical composition of  claim 39 , wherein the RNA: (i) is selected from non-replicating mRNA or virally-derived, self-amplifying RNA; and/or (ii) comprises a non-naturally occurring nucleotide or a modified nucleoside. 
     
     
         41 . A method of treating breast cancer, comprising administering the pharmaceutical composition of  claim 32  to an individual in need thereof.